Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, which projects using NHS data undertaken by (a) Novartis, (b) IQVIA, (c) AstraZeneca, (d) Merck, (e) Novo Nordisk, (f) GSK, (g) Roche and (h) Janssen-Cilag have adopted the (i) no value sharing, (ii) free or discounted products, (iii) royalty or revenue share, (iv) profit share, (v) intellectual property ownership share, (vi) equity share and (vii) fee for access NHS value sharing approaches.

The Department and the National Health Service in England are moving to a system of “data access as default” for secondary uses of NHS data, which is being supported by the implementation of Secure Data Environments (SDEs). This means that NHS data is increasingly accessed through secure platforms rather than shared with researchers.

Across the NHS Research SDE Network, which is a consortium of national and regional NHS-led SDEs, access to data is usually subject to a fee on a cost-recovery basis. Some SDEs are also exploring options of royalty or revenue sharing, profit sharing, intellectual property ownership sharing, and equity sharing. These approaches are supported by the Value Sharing Framework for NHS data partnerships, which sets out principles for NHS organisations to ensure fair value returns, including sharing in the value created by their data. Details of these are not collected centrally.

Each platform within the NHS Research SDE Network publishes a data use register that summarises the projects in progress, including those conducted by the commercial organisations referenced. Local data partnerships between NHS trusts and private companies outside the SDE network would not be collected on the same registers, and some details may be commercially sensitive.